Skip to main content
Top
Published in: Journal of Cancer Research and Clinical Oncology 6/2014

01-06-2014 | Original Article – Clinical Oncology

Estrogen receptor β2 is inversely correlated with Ki-67 in hyperplastic and noninvasive neoplastic breast lesions

Authors: Νiki Ι. Chantzi, Marina Palaiologou, Artemis Stylianidou, Nikos Goutas, Stamatis Vassilaros, Helen P. Kourea, Eugen Dhimolea, Dimitra J. Mitsiou, Dina G. Tiniakos, Μichael N. Alexis

Published in: Journal of Cancer Research and Clinical Oncology | Issue 6/2014

Login to get access

Abstract

Purpose

The purpose of the study is to compare expression levels of ΕRα, ERβ1, ERβ2 and cell proliferation marker Ki-67 in normal breast and hyperplastic and noninvasive neoplastic breast lesions.

Materials and methods

Routinely processed breast tissue from 55 patients provided 65 cases of noninvasive lesions, namely, epithelial hyperplasia of usual type (HUT), apocrine metaplasia (AM), atypical hyperplasia (AH) and ductal carcinoma in situ (DCIS) and 14 cases of adjacent normal breast tissue. Expression of ERα, ERβ1 and ERβ2 were evaluated using immunohistochemistry and correlated with Ki-67 labeling index (Ki-67 LI) and menopausal status of the patients.

Results

Compared with normal breast, ERα expression increased in low to intermediate-grade DCIS (DCIS1/2) and tended to decrease in high-grade DCIS, while ERβ1 expression decreased in DCIS irrespective of grade. Mean Ki-67 LI in HUT, low to intermediate-grade DCIS and high-grade DCIS was higher than in normal breast. Higher than normal Ki-67 LI correlated with low ERβ2 expression in the whole set of cases and with high ERα expression and low ERβ2 expression in the postmenopausal cases of the subset that is generated by excluding AM and high-grade DCIS. Postmenopausal status correlated with low ERβ1 expression in the whole set and with higher than normal Ki-67 LI, high ERα expression and low ERβ1 expression in the subset.

Conclusions

These findings are in accordance with an ERα-opposing oncosuppressive role of ERβ2 in mammary carcinogenesis along the HUT-AH-DCIS1/2 pathway.
Literature
go back to reference Bartella V, Rizza P, Barone I, Zito D, Giordano F, Giordano C, Catalano S, Mauro L, Sisci D, Panno ML, Fuqua SA, Andò S (2012) Estrogen receptor beta binds Sp1 and recruits a corepressor complex to the estrogen receptor alpha gene promoter. Breast Cancer Res Treat 134:569–581. doi:10.1007/s10549-012-2090-9 PubMedCrossRef Bartella V, Rizza P, Barone I, Zito D, Giordano F, Giordano C, Catalano S, Mauro L, Sisci D, Panno ML, Fuqua SA, Andò S (2012) Estrogen receptor beta binds Sp1 and recruits a corepressor complex to the estrogen receptor alpha gene promoter. Breast Cancer Res Treat 134:569–581. doi:10.​1007/​s10549-012-2090-9 PubMedCrossRef
go back to reference Chang EC, Frasor J, Komm B, Katzenellenbogen BS (2006) Impact of estrogen receptor beta on gene networks regulated by estrogen receptor alpha in breast cancer cells. Endocrinology 147:4831–4842. doi:10.1210/en.2006-0563 PubMedCrossRef Chang EC, Frasor J, Komm B, Katzenellenbogen BS (2006) Impact of estrogen receptor beta on gene networks regulated by estrogen receptor alpha in breast cancer cells. Endocrinology 147:4831–4842. doi:10.​1210/​en.​2006-0563 PubMedCrossRef
go back to reference Chantzi NI, Meligova AK, Dhimolea E, Petrou CC, Mitsiou DJ, Magafa V, Pechtelidou A, Florentin I, Kitraki E, Cordopatis P, Tiniakos DG, Alexis MN (2011) Insights into ectopic estrogen receptor expression, nucleocytoplasmic distribution and interaction with chromatin obtained with new antibodies to estrogen receptors α and β. Steroids 76:974–985. doi:10.1016/j.steroids.2011.05.010 PubMedCrossRef Chantzi NI, Meligova AK, Dhimolea E, Petrou CC, Mitsiou DJ, Magafa V, Pechtelidou A, Florentin I, Kitraki E, Cordopatis P, Tiniakos DG, Alexis MN (2011) Insights into ectopic estrogen receptor expression, nucleocytoplasmic distribution and interaction with chromatin obtained with new antibodies to estrogen receptors α and β. Steroids 76:974–985. doi:10.​1016/​j.​steroids.​2011.​05.​010 PubMedCrossRef
go back to reference Chantzi NI, Tiniakos DG, Palaiologou M, Goutas N, Filippidis T, Vassilaros SD, Dhimolea E, Mitsiou DJ, Alexis MN (2013) Estrogen receptor beta 2 is associated with poor prognosis in estrogen receptor alpha-negative breast carcinoma. J Cancer Res Clin Oncol 139:1489–1498. doi:10.1007/s00432-013-1467-4 PubMedCrossRef Chantzi NI, Tiniakos DG, Palaiologou M, Goutas N, Filippidis T, Vassilaros SD, Dhimolea E, Mitsiou DJ, Alexis MN (2013) Estrogen receptor beta 2 is associated with poor prognosis in estrogen receptor alpha-negative breast carcinoma. J Cancer Res Clin Oncol 139:1489–1498. doi:10.​1007/​s00432-013-1467-4 PubMedCrossRef
go back to reference Claus EB, Chu P, Howe CL, Davison TL, Stern DF, Carter D, DiGiovanna MP (2001) Pathobiologic findings in DCIS of the breast: morphologic features, angiogenesis, HER-2/neu and hormone receptors. Exp Mol Pathol 70:303–316. doi:10.1006/exmp.2001.2366 PubMedCrossRef Claus EB, Chu P, Howe CL, Davison TL, Stern DF, Carter D, DiGiovanna MP (2001) Pathobiologic findings in DCIS of the breast: morphologic features, angiogenesis, HER-2/neu and hormone receptors. Exp Mol Pathol 70:303–316. doi:10.​1006/​exmp.​2001.​2366 PubMedCrossRef
go back to reference Honma N, Horii R, Iwase T, Saji S, Younes M, Takubo K, Matsuura M, Ito Y, Akiyama F, Sakamoto G (2008) Clinical importance of estrogen receptor-beta evaluation in breast cancer patients treated with adjuvant tamoxifen therapy. J Clin Oncol 26:3727–3734. doi:10.1200/JCO.2007.14.2968 PubMedCrossRef Honma N, Horii R, Iwase T, Saji S, Younes M, Takubo K, Matsuura M, Ito Y, Akiyama F, Sakamoto G (2008) Clinical importance of estrogen receptor-beta evaluation in breast cancer patients treated with adjuvant tamoxifen therapy. J Clin Oncol 26:3727–3734. doi:10.​1200/​JCO.​2007.​14.​2968 PubMedCrossRef
go back to reference Moore JT, McKee DD, Slentz-Kesler K, Moore LB, Jones SA, Horne EL, Su JL, Kliewer SA, Lehmann JM, Willson TM (1998) Cloning and characterization of human estrogen receptor beta isoforms. Biochem Biophys Res Commun 247:75–78PubMedCrossRef Moore JT, McKee DD, Slentz-Kesler K, Moore LB, Jones SA, Horne EL, Su JL, Kliewer SA, Lehmann JM, Willson TM (1998) Cloning and characterization of human estrogen receptor beta isoforms. Biochem Biophys Res Commun 247:75–78PubMedCrossRef
go back to reference Morelli C, Lanzino M, Garofalo C, Maris P, Brunelli E, Casaburi I, Catalano S, Bruno R, Sisci D, Andò S (2010) Akt2 inhibition enables the forkhead transcription factor FoxO3a to have a repressive role in estrogen receptor alpha transcriptional activity in breast cancer cells. Mol Cell Biol 30:857–8570. doi:10.1128/MCB.00824-09 PubMedCentralPubMedCrossRef Morelli C, Lanzino M, Garofalo C, Maris P, Brunelli E, Casaburi I, Catalano S, Bruno R, Sisci D, Andò S (2010) Akt2 inhibition enables the forkhead transcription factor FoxO3a to have a repressive role in estrogen receptor alpha transcriptional activity in breast cancer cells. Mol Cell Biol 30:857–8570. doi:10.​1128/​MCB.​00824-09 PubMedCentralPubMedCrossRef
go back to reference Novelli F, Milella M, Melucci E, Di Benedetto A, Sperduti I, Perrone-Donnorso R, Perracchio L, Venturo I, Nisticò C, Fabi A, Buglioni S, Natali PG, Mottolese M (2008) A divergent role for estrogen receptor-beta in node-positive and node-negative breast cancer classified according to molecular subtypes: an observational prospective study. Breast Cancer Res 10:R74. doi:10.1186/bcr2139 PubMedCentralPubMedCrossRef Novelli F, Milella M, Melucci E, Di Benedetto A, Sperduti I, Perrone-Donnorso R, Perracchio L, Venturo I, Nisticò C, Fabi A, Buglioni S, Natali PG, Mottolese M (2008) A divergent role for estrogen receptor-beta in node-positive and node-negative breast cancer classified according to molecular subtypes: an observational prospective study. Breast Cancer Res 10:R74. doi:10.​1186/​bcr2139 PubMedCentralPubMedCrossRef
go back to reference Palmieri C, Lam EW, Mansi J, MacDonald C, Shousha S, Madden P, Omoto Y, Sunters A, Warner M, Gustafsson JA, Coombes RC (2004) The expression of ER beta cx in human breast cancer and the relationship to endocrine therapy and survival. Clin Cancer Res 10:2421–2428. doi:10.1158/1078-0432.CCR-03-0215 PubMedCrossRef Palmieri C, Lam EW, Mansi J, MacDonald C, Shousha S, Madden P, Omoto Y, Sunters A, Warner M, Gustafsson JA, Coombes RC (2004) The expression of ER beta cx in human breast cancer and the relationship to endocrine therapy and survival. Clin Cancer Res 10:2421–2428. doi:10.​1158/​1078-0432.​CCR-03-0215 PubMedCrossRef
go back to reference Park BW, Kim KS, Heo MK, Yang WI, Kim SI, Kim JH, Kim GE, Lee KS (2006) The changes of estrogen receptor-beta variants expression in breast carcinogenesis: decrease of estrogen receptor-beta2 expression is the key event in breast cancer development. J Surg Oncol 93:504–510. doi:10.1002/jso.20336 PubMedCrossRef Park BW, Kim KS, Heo MK, Yang WI, Kim SI, Kim JH, Kim GE, Lee KS (2006) The changes of estrogen receptor-beta variants expression in breast carcinogenesis: decrease of estrogen receptor-beta2 expression is the key event in breast cancer development. J Surg Oncol 93:504–510. doi:10.​1002/​jso.​20336 PubMedCrossRef
go back to reference Paruthiyil S, Parmar H, Kerekatte V, Cunha GR, Firestone GL, Leitman DC (2004) Estrogen receptor beta inhibits human breast cancer cell proliferation and tumor formation by causing a G2 cell cycle arrest. Cancer Res 64:423–428. doi:10.1158/0008-5472.CAN-03-2446 PubMedCrossRef Paruthiyil S, Parmar H, Kerekatte V, Cunha GR, Firestone GL, Leitman DC (2004) Estrogen receptor beta inhibits human breast cancer cell proliferation and tumor formation by causing a G2 cell cycle arrest. Cancer Res 64:423–428. doi:10.​1158/​0008-5472.​CAN-03-2446 PubMedCrossRef
go back to reference Rhodes A, Jasani B, Balaton AJ, Miller KD (2000) Immunohistochemical demonstration of oestrogen and progesterone receptors: correlation of standards achieved on in house tumours with that achieved on external quality assessment material in over 150 laboratories from 26 countries. J Clin Pathol 53:292–301. doi:10.1136/jcp.53.4.292 PubMedCentralPubMedCrossRef Rhodes A, Jasani B, Balaton AJ, Miller KD (2000) Immunohistochemical demonstration of oestrogen and progesterone receptors: correlation of standards achieved on in house tumours with that achieved on external quality assessment material in over 150 laboratories from 26 countries. J Clin Pathol 53:292–301. doi:10.​1136/​jcp.​53.​4.​292 PubMedCentralPubMedCrossRef
go back to reference Rody A, Holtrich U, Solbach C, Kourtis K, von Minckwitz G, Engels K, Kissler S, Gätje R, Karn T, Kaufmann M (2005) Methylation of estrogen receptor beta promoter correlates with loss of ER-beta expression in mammary carcinoma and is an early indication marker in premalignant lesions. Endocr Relat Cancer 12:903–916. doi:10.1677/erc.1.01088 PubMedCrossRef Rody A, Holtrich U, Solbach C, Kourtis K, von Minckwitz G, Engels K, Kissler S, Gätje R, Karn T, Kaufmann M (2005) Methylation of estrogen receptor beta promoter correlates with loss of ER-beta expression in mammary carcinoma and is an early indication marker in premalignant lesions. Endocr Relat Cancer 12:903–916. doi:10.​1677/​erc.​1.​01088 PubMedCrossRef
go back to reference Roger P, Sahla ME, Mäkelä S, Gustafsson JA, Baldet P, Rochefort H (2001) Decreased expression of estrogen receptor beta protein in proliferative preinvasive mammary tumors. Cancer Res 61:2537–2541PubMed Roger P, Sahla ME, Mäkelä S, Gustafsson JA, Baldet P, Rochefort H (2001) Decreased expression of estrogen receptor beta protein in proliferative preinvasive mammary tumors. Cancer Res 61:2537–2541PubMed
go back to reference Román-Pérez E, Casbas-Hernández P, Pirone JR, Rein J, Carey LA, Lubet RA, Mani SA, Amos KD, Troester MA (2012) Gene expression in extratumoral microenvironment predicts clinical outcome in breast cancer patients. Breast Cancer Res 14:R51. doi:10.1186/bcr3152 PubMedCentralPubMedCrossRef Román-Pérez E, Casbas-Hernández P, Pirone JR, Rein J, Carey LA, Lubet RA, Mani SA, Amos KD, Troester MA (2012) Gene expression in extratumoral microenvironment predicts clinical outcome in breast cancer patients. Breast Cancer Res 14:R51. doi:10.​1186/​bcr3152 PubMedCentralPubMedCrossRef
go back to reference Shaaban AM, Sloane JP, West CR, Foster CS (2002) Breast cancer risk in usual ductal hyperplasia is defined by estrogen receptor-alpha and Ki-67 expression. Am J Pathol 60:597–604CrossRef Shaaban AM, Sloane JP, West CR, Foster CS (2002) Breast cancer risk in usual ductal hyperplasia is defined by estrogen receptor-alpha and Ki-67 expression. Am J Pathol 60:597–604CrossRef
go back to reference Shaaban AM, O’Neill PA, Davies MP, Sibson R, West CR, Smith PH, Foster CS (2003) Declining estrogen receptor-beta expression defines malignant progression of human breast neoplasia. Am J Surg Pathol 27:1502–1512PubMedCrossRef Shaaban AM, O’Neill PA, Davies MP, Sibson R, West CR, Smith PH, Foster CS (2003) Declining estrogen receptor-beta expression defines malignant progression of human breast neoplasia. Am J Surg Pathol 27:1502–1512PubMedCrossRef
go back to reference Shaaban AM, Jarvis C, Moore F, West C, Dodson A, Foster CS (2005) Prognostic significance of estrogen receptor Beta in epithelial hyperplasia of usual type with known outcome. Am J Surg Pathol 29:1593–1599PubMedCrossRef Shaaban AM, Jarvis C, Moore F, West C, Dodson A, Foster CS (2005) Prognostic significance of estrogen receptor Beta in epithelial hyperplasia of usual type with known outcome. Am J Surg Pathol 29:1593–1599PubMedCrossRef
go back to reference Shaaban AM, Green AR, Karthik S, Alizadeh Y, Hughes TA, Harkins L, Ellis IO, Robertson JF, Paish EC, Saunders PT, Groome NP, Speirs V (2008) Nuclear and cytoplasmic expression of ERbeta1, ERbeta2, and ERbeta5 identifies distinct prognostic outcome for breast cancer patients. Clin Cancer Res 14:5228–5235. doi:10.1158/1078-0432.CCR-07-4528 PubMedCrossRef Shaaban AM, Green AR, Karthik S, Alizadeh Y, Hughes TA, Harkins L, Ellis IO, Robertson JF, Paish EC, Saunders PT, Groome NP, Speirs V (2008) Nuclear and cytoplasmic expression of ERbeta1, ERbeta2, and ERbeta5 identifies distinct prognostic outcome for breast cancer patients. Clin Cancer Res 14:5228–5235. doi:10.​1158/​1078-0432.​CCR-07-4528 PubMedCrossRef
go back to reference Sharma P, Kimler BF, Warner C, Metheny T, Xue Q, Zalles CM, Fabian CJ (2006) Estrogen receptor expression in benign breast ductal cells obtained from random periareolar fine needle aspiration correlates with menopausal status and cytomorphology index score. Breast Cancer Res Treat 100:71–76. doi:10.1007/s10549-006-9234-8 PubMedCrossRef Sharma P, Kimler BF, Warner C, Metheny T, Xue Q, Zalles CM, Fabian CJ (2006) Estrogen receptor expression in benign breast ductal cells obtained from random periareolar fine needle aspiration correlates with menopausal status and cytomorphology index score. Breast Cancer Res Treat 100:71–76. doi:10.​1007/​s10549-006-9234-8 PubMedCrossRef
go back to reference Zhao C, Matthews J, Tujague M, Wan J, Ström A, Toresson G, Lam EW, Cheng G, Gustafsson JA, Dahlman-Wright K (2007) Estrogen receptor beta2 negatively regulates the transactivation of estrogen receptor alpha in human breast cancer cells. Cancer Res 67:3955–3962. doi:10.1158/0008-5472.CAN-06-3505 PubMedCrossRef Zhao C, Matthews J, Tujague M, Wan J, Ström A, Toresson G, Lam EW, Cheng G, Gustafsson JA, Dahlman-Wright K (2007) Estrogen receptor beta2 negatively regulates the transactivation of estrogen receptor alpha in human breast cancer cells. Cancer Res 67:3955–3962. doi:10.​1158/​0008-5472.​CAN-06-3505 PubMedCrossRef
go back to reference Zou Y, Tsai WB, Cheng CJ, Hsu C, Chung YM, Li PC, Lin SH, Hu MC (2008) Forkhead box transcription factor FOXO3a suppresses estrogen-dependent breast cancer cell proliferation and tumorigenesis. Breast Cancer Res 10:R21. doi:10.1186/bcr1872 PubMedCentralPubMedCrossRef Zou Y, Tsai WB, Cheng CJ, Hsu C, Chung YM, Li PC, Lin SH, Hu MC (2008) Forkhead box transcription factor FOXO3a suppresses estrogen-dependent breast cancer cell proliferation and tumorigenesis. Breast Cancer Res 10:R21. doi:10.​1186/​bcr1872 PubMedCentralPubMedCrossRef
Metadata
Title
Estrogen receptor β2 is inversely correlated with Ki-67 in hyperplastic and noninvasive neoplastic breast lesions
Authors
Νiki Ι. Chantzi
Marina Palaiologou
Artemis Stylianidou
Nikos Goutas
Stamatis Vassilaros
Helen P. Kourea
Eugen Dhimolea
Dimitra J. Mitsiou
Dina G. Tiniakos
Μichael N. Alexis
Publication date
01-06-2014
Publisher
Springer Berlin Heidelberg
Published in
Journal of Cancer Research and Clinical Oncology / Issue 6/2014
Print ISSN: 0171-5216
Electronic ISSN: 1432-1335
DOI
https://doi.org/10.1007/s00432-014-1652-0

Other articles of this Issue 6/2014

Journal of Cancer Research and Clinical Oncology 6/2014 Go to the issue

Original Article – Clinical Oncology

Primary malignant cardiac tumors

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.